Spoken Alpha
Ensysce Biosciences, Inc.
Ensysce Biosciences develops pharmaceutical products designed to reduce opioid abuse and overdose risk. The company's lead candidate, PF614, is a chemically modified oxycodone that releases only when exposed to digestive enzymes, resisting injection and nasal abuse.
Ensysce Biosciences, Inc.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ENSCW, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENSCW.
$ curl https://api.spokenalpha.com/v1/companies/ENSCWFAQ
Spoken Alpha indexes ENSCW's earnings call transcripts at https://spokenalpha.com/companies/ENSCW. Each call links to attributed speakers and parsed analyst Q&A. Ensysce Biosciences, Inc.'s own investor relations page is at https://ir.ensysce.com/.